Economic evaluations of contingency management in illicit drug misuse programmes: A systematic review

Drug and Alcohol Review

Volumn 34, Issue 3, 2015, Pages 289-298

  Shearer, James ^a   Tie, Hiong ^a   Byford, Sarah ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Contingency management; Economic evaluation; Review

Indexed keywords

BEHAVIOR THERAPY; COST BENEFIT ANALYSIS; DRUG USE; ECONOMICS; HUMAN; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

BEHAVIOR THERAPY; COST-BENEFIT ANALYSIS; DRUG USERS; HUMANS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84928717186     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12240     Document Type: Review

References (33)

1. Rehm J, Baliunas D, Brochu S, etal. The costs of substance abuse in Canada, 2002. Ottawa: Canadian Centre on Substance Abuse, 2006.
2. Collins D, Lapsley H. The costs of tobacco, alcohol and illicit drug abuse to Australian society in 2004/2005. Canberra: Commonwealth of Australia, 2008.
3. National Drug Intelligence Center. The economic impact of illicit drug use on American society. Washington, DC: United States Department of Justice, 2011.
4. Gordon L, Tinsley L, Godfrey C, Parrott S. The economic and social costs of class A drug use in England and Wales, 2003/2004. In: Singleton N, Murray R, Tinsley L, eds. Measuring different aspects of problem drug use: methodological developments, 2nd edn. London: Home Office, 2006:41-45. Home Office Online Report 16/06.
5. NICE. NICE clinical guideline 51: drug misuse psychosocial interventions. London: National Institute for Health and Care Excellence, 2007.
6. Home Office. Drugs: protecting families and communities. London: Home Office, 2008.
7. Petry N. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug Alcohol Depend 2000;58:9-25.
8. Plebani Lussier J, Heil S, Mongeon J, Badger G, Higgins S. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 2006;100:192-203.
9. Prendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction 2006;101:1546-1560.
10. Dutra L, Stathopoulou G, Basden S, Leyro T, Powers M, Otto M. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165:179-187.
11. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005.
12. Barnett PG, Masson CL, Sorensen JL, Wong W, Hall S. Linking opioid-dependent hospital patients to drug treatment: health care use and costs 6 months after randomization. Addiction 2006;101:1797-1804.
13. Bradley C, French M, Rachal J. Financing and cost of standard and enhanced methadoen treatment. J Subst Abuse Treat 1994;11:433-442.
14. Shoptaw S, Klausner JD, Reback CJ, etal. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC Public Health 2006;6:214.
15. Olmstead TA, Cohen JP, Petry NM. Health-care service utilization in substance abusers receiving contingency management and standard care treatments. Addiction 2012;107:1462-1470.
16. Liberati A, Altman DG, Tetzlaff J, etal. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-94.
17. Olmstead TA, Sindelar JL, Easton CJ, Carroll KM. The cost-effectiveness of four treatments for marijuana dependence. Addiction 2007;102:1443-1453.
18. Olmstead TA, Sindelar JL, Petry NM. Clinic variation in the cost-effectiveness of contingency management. Am J Addict 2007;16:457-460.
19. Olmstead TA, Petry NM. The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine- or opioid-dependent outpatients. Drug Alcohol Depend 2009;102:108-115.
20. Sindelar J, Elbel B, Petry NM. What do we get for our money? Cost-effectiveness of adding contingency management. Addiction 2007;102:309-316.
21. Sindelar JL, Olmstead TA, Peirce JM. Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction 2007;102:1463-1471.
22. Barnett PG, Sorensen JL, Wong W, Haug NA, Hall SM. Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV. Drug Alcohol Depend 2009;100:115-121.
23. Hartz DT, Meek P, Piotrowski NA, etal. A cost-effectiveness and cost-benefit analysis of contingency contracting-enhanced methadone detoxification treatment. Am J Drug Alcohol Abuse 1999;25:207-218.
24. Sheidow AJ, Jayawardhana J, Bradford W, Henggeler SW, Shapiro SB. Money matters: cost-effectiveness of juvenile drug court with and without evidence-based treatments. J Child Adolesc Subst Abuse 2012;21:69-90.
25. Olmstead TA, Sindelar JL, Petry NM. Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs. Drug Alcohol Depend 2007;87:175-182.
26. Schumacher JE, Mennemeyer ST, Milby JB, Wallace D, Nolan K. Costs and effectiveness of substance abuse treatments for homeless persons. J Ment Health Policy Econ 2002;5:33-42.
27. Fenwick E, Byford S. A guide to cost-effectiveness acceptability curves. Br J Psychiatry 2005;187:106-108.
28. Bullock K, Mann D, Street R, Coxon C. Examining attrition in confiscating the proceeds of crime. London: Home Office, 2009. Research Report 17.
29. NICE. Guide to the methods of technology appraisal. Excellence. London: National Institute for Health and Care Excellence, 2013.
30. Byford S, Barrett B, Metrebian N, etal. Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. Br J Psychiatry 2013;203:341-349.
31. Zarkin G, Johnson R, Larison C, Harwoos H, Fountain D. Benefits and costs of methadone treatment: results from a lifetime simulation model. Health Econ 2005;14:1133-1150.
32. Sindelar J, Jofre-Bonet M, French M, McLellan A. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes. Drug Alcohol Depend 2004;73:41-50.
33. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.